Rhumbline Advisers bought a new position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 9,577 shares of the company’s stock, valued at approximately $303,000.
A number of other large investors have also recently added to or reduced their stakes in RETA. Teachers Advisors LLC grew its holdings in Reata Pharmaceuticals by 12.8% during the fourth quarter. Teachers Advisors LLC now owns 10,116 shares of the company’s stock worth $221,000 after acquiring an additional 1,148 shares during the period. Bank of New York Mellon Corp grew its holdings in Reata Pharmaceuticals by 18.1% during the first quarter. Bank of New York Mellon Corp now owns 22,213 shares of the company’s stock worth $503,000 after acquiring an additional 3,407 shares during the period. Victory Capital Management Inc. acquired a new position in Reata Pharmaceuticals during the first quarter worth about $483,000. FMR LLC grew its holdings in Reata Pharmaceuticals by 40.6% during the first quarter. FMR LLC now owns 237,606 shares of the company’s stock worth $5,382,000 after acquiring an additional 68,600 shares during the period. Finally, Fifth Third Bancorp acquired a new position in Reata Pharmaceuticals during the first quarter worth about $395,000. 15.56% of the stock is currently owned by hedge funds and other institutional investors.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) opened at 31.57 on Wednesday. The company has a 50-day moving average price of $30.03 and a 200-day moving average price of $27.38. Reata Pharmaceuticals, Inc. has a 52 week low of $18.51 and a 52 week high of $41.60. The stock’s market cap is $824.07 million.
TRADEMARK VIOLATION NOTICE: “Rhumbline Advisers Buys New Holdings in Reata Pharmaceuticals, Inc. (RETA)” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://stocknewstimes.com/2017/10/11/rhumbline-advisers-buys-new-holdings-in-reata-pharmaceuticals-inc-reta.html.
In related news, Director James Edward Bass acquired 8,064 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average price of $31.00 per share, for a total transaction of $249,984.00. Following the completion of the acquisition, the director now owns 67,411 shares of the company’s stock, valued at approximately $2,089,741. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 62.40% of the company’s stock.
A number of research firms recently issued reports on RETA. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $61.00 target price (up from $55.00) on shares of Reata Pharmaceuticals in a report on Wednesday, July 26th. ValuEngine lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Robert W. Baird reaffirmed an “outperform” rating and set a $47.00 target price (up from $43.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Jefferies Group LLC reaffirmed a “buy” rating and set a $44.00 target price on shares of Reata Pharmaceuticals in a report on Friday, October 6th. Finally, Piper Jaffray Companies lifted their target price on Reata Pharmaceuticals from $53.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, July 24th. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $54.71.
Reata Pharmaceuticals Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals, Inc. (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.